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Abstract
Aim To examine the impact of structured self-monitoring of blood glucose, with or without TeleCare support, on
glycaemic control in people with sub-optimally controlled Type 2 diabetes.
Methods We conducted a 12-month, multicentre, randomized controlled trial in people with established (>1 year) Type
2 diabetes not on insulin therapy, with sub-optimal glycaemic control [HbA1c ≥58 to ≤119 mmol/mol (≥7.5% to
≤13%)]. A total of 446 participants were randomized to a control group (n =151) receiving usual diabetes care, a group
using structured self-monitoring of blood glucose alone (n =147) or a group using structured self-monitoring of blood
glucose with additional monthly ‘TeleCare’ support (n =148). The primary outcome was HbA1c at 12 months.
Results A total of 323 participants (72%) completed the study; 116 (77%) in the control group, 99 (67%) in the self-
monitoring of blood glucose alone group and 108 (73%) in the self-monitoring of blood glucose plus TeleCare group.
Compared tobaseline, themeanHbA1cwas lower inall groups at12months,with reductionsof3.3mmol/mol (95%CI–5.71
to –0.78) or 0.3% (95%CI –0.52 to –0.07; P=0.01) in the control group, 11.4mmol/mol (95%CI –14.11 to –8.76) or 1.1%
(–1.29 to –0.81; P<0.0001) in the group using self-monitoring of blood glucose alone and 12.8 mmol/mol (95% CI –15.34
to –10.31) or 1.2% (95% CI –1.40 to -0.94; P<0.0001) in the group using self-monitoring of blood glucose plus TeleCare.
This represents a reduction inHbA1c of 8.9mmol/mol (95%CI –11.97 to –5.84) or 0.8%(95%CI –1.10 to -0.54;P≤0.0001)
with structured self-monitoring of blood glucose compared to the control group. Participants with lower baseline HbA1c,
shorter duration of diabetes and higher educational achievement were more likely to achieve HbA1c ≤53mmol/mol (7.0%).
Conclusions Structured self-monitoring of blood glucose provides clinical and statistical improvements in glycaemic
control in Type 2 diabetes. No additional benefit, over and above the use of structured self-monitoring of blood glucose,
was observed in glycaemic control with the addition of once-monthly TeleCare support.
(Clinical trial registration no.: ISRCTN21390608)
Diabet. Med. 00: 1–13 (2019)
Introduction
It is recognized that self-monitoring of blood glucose
(SMBG) helps to improve glycaemic control and identify
hypoglycaemia in people with Type 1 and Type 2 diabetes
treated with insulin, whilst there is ongoing debate regarding
the clinical benefits of using SMBG in those with Type 2
diabetes who are not on insulin therapy [1]. Many studies
and meta-analyses have been conducted since the first
evaluation of SMBG in 1983 [2], with little consensus on
the benefit, in part because of the variation in intervention
regimens and study populations [3–18]. In 2009, the Inter-
national Diabetes Federation guidelines on SMBG use in
non-insulin-treated Type 2 diabetes presented evidence
supporting structured blood glucose (BG) monitoring
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combined with appropriate action [19]. This emphasized the
need for both healthcare professionals and people with Type
2 diabetes to be suitably informed and willing to conduct and
incorporate paired (pre- and postprandial) BG profiles into
diabetes care plans. Despite additional evidence in support of
structured SMBG [8], SMBG is still being introduced into
clinical trials and practice in an unstructured way, with little
benefit [20]. Currently, regulatory authorities recommend
limiting the use of SMBG in people with Type 2 diabetes not
on insulin therapy to testing for hypoglycaemia, limiting
SMBG to a safety role instead of it being an integral part of
self-management [21,22].
The concept of telemedicine, that is using telecommunica-
tions to deliver health services, has become increasingly
popular, and many studies have incorporated features of
telemedicine into studies on diabetes management showing
improvement in glycaemic control when compared to usual
care [23]. The form of communication used and level of
interactivity are thought to have an impact on the effective-
ness of the telemedicine intervention, with methods allowing
two-way communication between the healthcare provider/
person with diabetes proving more successful.
We conducted a randomized controlled trial (RCT) to
determine if the use of structured SMBG in a large popula-
tion of people with Type 2 diabetes not on insulin therapy
would improve HbA1c over 12 months, compared to a
control group receiving usual care as per NICE guidelines,
and also whether the addition of a monthly telephone
consultation with a trained study nurse (TeleCare) provided
additional glycaemic benefit.
Participants and methods
Full details of the study protocol have been published
previously [24]. In brief, the SMBG Study was an open,
multicentre RCT. Participants had sub-optimally controlled
Type 2 diabetes, were not receiving insulin therapy and were
involved in the study for 12 months after randomization to
one of three groups: a control group, a group performing
SMBG alone or a group performing SMBG and receiving
TeleCare (Fig. 1). The study was conducted across 16 sites,
nine of which were general practices and seven of which were
based within hospitals across Wales and England. All
participants remained under the care of their general prac-
titioner (GP) throughout the course of the study, and
medication changes were prescribed by the GP when
recommended by the local study team.
The South EastWales Research Ethics Committee (Panel C)
gave ethical approval for the study (Ref. 10/WSE03/50).
Participants
Participants were aged between 18 and 80 years, having been
diagnosed with Type 2 diabetes for at least 1 year. HbA1c at
baseline was 58 to 119 mmol/mol (7.5–13%) and partici-
pants were not receiving insulin therapy. Those who, in the
opinion of their GP, needed to monitor their BG for clinical
reasons were excluded from the study, but those using SMBG
for safety reasons, in line with UK Driver and Vehicle
Licensing Agency guidance, were eligible to be enrolled.
Procedures
The study procedures are shown in Fig. 1. Written informed
consent was provided by all participants prior to any study
activities taking place, following a full written and oral
explanation of the study. Randomization was performed
remotely by Swansea Trials Unit via email using a central
database. Study site and previous experience of using SMBG
(Yes/No) were used as stratifying factors for randomization.
The allocation sequence was generated dynamically to
maintain an approximate balance of 1:1:1 across the three
groups overall. The participants randomized to the control
group (Group 1) received their usual care and had contact
with their diabetes team, GP or hospital clinic, as normal.
Routine HbA1c results were used to facilitate glycaemic
management by their GP as per usual care. All participants
attended the 3-monthly study visits, which involved collect-
ing clinical data, taking a blood sample to measure HbA1c
and total cholesterol levels, the completion of participant-
reported outcome measures (not reported in the present
paper) and review of the participant diary in which signif-
icant events, medication changes and contact with healthcare
professionals were recorded. General diabetes education was
provided by a study nurse during the baseline visit after all
questionnaires had been completed and prior to randomiza-
tion. The study nurses used the ‘Your Guide to Type 2
Diabetes’ education booklet produced by Diabetes UK for
people living with diabetes to ensure consistency of infor-
mation [25]. The booklet provided an explanation of Type 2
What’s new?
• This 12-month randomized controlled trial examined
the impact of structured self-monitoring of blood
glucose (SMBG), with and without TeleCare support,
on glycaemic control in people with sub-optimally
controlled Type 2 diabetes.
• Results showed that this standardized, structured
SMBG intervention, with or without additional Tele-
Care, provided statistically and clinically significant
improvements in glycaemic control.
• Structured SMBG should be offered as part of the self-
management process for all people with sub-optimally
controlled Type 2 diabetes, even when not treated with
insulin. Unstructured SMBG (other than for safety
purposes) should be regarded as a waste of valuable
time and resources.
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diabetes and an overview of how the various diabetes
medications work and how they should be taken. It also
provided information on BG control, food, weight manage-
ment, living well with diabetes and complications. Study
nurses went through the booklet with each participant,
highlighting information relevant to the individual and
answering any questions. The education session was tailored
to the needs of each participant and took an average of 1
hour, in conjunction with the baseline visit. All participants
were given a copy of the Diabetes UK booklet to keep for
their personal reference and use throughout the study.
Diabetes-related questions that arose throughout the study
were discussed with reference to the booklet.
Participants in the two SMBG groups (groups 2 and 3)
attended an additional study visit (visit 2a) compared to
those in the control group in order to undertake structured
SMBG training (Fig. S1). Instruction was given on the correct
method for taking and measuring BG. Thereafter, the
participants were asked to measure their BG levels after
fasting, 2 h after breakfast, and before and 2 h after their
main meal on 2 days each week. During the week prior to the
3-monthly study visits, participants were asked to perform a
seven-point BG profile (before and 2 h after three main
meals, and at bedtime) on 3 days. At each study visit BG
meters were downloaded and a calibration check carried out.
All participants in the SMBG groups were offered the Accu-
Chek 360° Diabetes Management System software (as used
by the study nurses) to use at home if they wished.
Participants in the SMBG groups were asked to record
their BG readings on the Accu-Chek 360° View Tool, a paper
tool used to produce daily profiles of BG readings. They were
shown how to interpret their SMBG results, how to identify
patterns of glycaemic abnormalities and how to deal with
abnormal glycaemic patterns. A stepped approach was taken,
taking action to first correct any patterns of hypoglycaemia,
then fasting hyperglycaemia and then post-meal hypergly-
caemia. Standardized algorithms were provided to the
participants (Fig. S2) and the study nurses and physicians
to guide decisions around lifestyle and/or medication adjust-
ment (Figs S3 and S4). All actions taken in response to the
BG monitoring were recorded. At each study visit, for those
in the SMBG groups, glycaemic management was based on
SMBG results alone, with a care plan developed for the
coming month(s) in partnership between the participant and
study nurse, based on the adopted algorithms.
In addition to the education and support provided to group
2 (SMBG alone) participants, those in group 3 (SMBG plus
TeleCare) were contacted by telephone at an agreed time
each month by their study nurse to review the previous
months’ BG readings and related events. Those who chose to
use the Accu-Chek 360° software were able to download
their meter to their own computer and securely email the BG
results to the study nurse in advance of their TeleCare
consultation. Those who chose not to use the software
reported their readings verbally over the phone, which were
then verified at the next study visit. At each consultation,
patterns of glycaemic abnormalities were identified and
explored jointly by the participant and study nurse, and a
care plan was then co-produced for the coming month which
was documented by the participant in their diary.
All study nurses attended a standardized training pro-
gramme delivered by the research team in addition to
Established poorly controlled T2DM 
HbA1c ≥ 7.5% / 58mmol/ mol
No SMBG
(Group 1)
SMBG + TeleCare
(Group 3)
SMBG Alone
(Group 2)
Normal contact with
diabetes care team
TeleCare
Support
3 monthly HbA1c, cholesterol, weight, QoL
7 point SMBG & care planning for SMBG groups only
12 month visit
Patient Group
Treatment Groups
Randomization
Diabetes Education
3, 6 & 9 month visits
End of Study
SMBG Education
Technical / Interpretive skills training
Assess and provide information for general diabetes 
educational needs (not to include SMBG education)
FIGURE 1 Study design flow chart. QoL, quality of life; SMBG, self-monitoring of blood glucose; T2DM, type 2 diabetes.
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successfully completing an online treatment management
programme (Virtual College Healthcare e-Academy, Safe Use
of Non-Insulin Therapies). Refresher training was provided
to the study staff approximately every 4 months at study
update meetings.
Outcomes
The primary outcome for the study was HbA1c at 12 months
in those who undertook SMBG and the control group. All
blood samples were sent to a central Good Clinical Labo-
ratory Practice accredited laboratory for analysis. All study
HbA1c results remained blinded to all participants, their
study team and diabetes team throughout the study. Final
HbA1c results were reported after participation in the study
was completed.
Secondary comparative outcomes included: HbA1c at 3, 6
and 9 months; percentage of people achieving the HbA1c
target of ≤53 mmol/mol (7%) at 12 months; and total serum
cholesterol, weight, BMI and waist circumference at 3, 6, 9
and 12 months. Whenever insulin therapy was required,
those participants were withdrawn from further participa-
tion in the study. Outcome measures specific to the SMBG
groups included confirmed episodes of BG < 4.5 mmol/l and
acceptability of SMBG. In those in the SMBG groups,
attitudes towards SMBG were ascertained using locally
derived questionnaires at randomization (SMBG 8) and at
each subsequent study visit (SMBG 14). These questionnaires
contained eight and 14 items, respectively, and included
questions on attitudes towards SMBG, action taken as a
result of the BG readings and confidence in their ability to
take action. The questionnaires were self-completed and the
responses were recorded to each item as yes/no/don’t know.
Sample size
The sample size calculation has been published previously
[24]. Assuming an effect size of 0.333, attrition of 20% with
0.05 significance and 0.8 power, a sample size of 398 would
be required to achieve the study primary aim. A conservative
and pragmatic sample size of 450 (n=150 per treatment
group) was adopted, which allowed an attrition rate of
~30%.
Statistical analysis
Participants who completed the study were analysed accord-
ing to their allocated group. To answer the primary objec-
tive, data from the two SMBG groups were pooled for
comparison with the control group, as prespecified in the
statistical analysis plan. As a result of the inclusion criteria,
HbA1c data were positively skewed, confirmed by residuals
from a linear mixed model for repeated measures; the
robustness of findings was therefore assessed using two data
transformations (square root, natural log). Analyses of the
transformed data led to the same conclusion regarding the
intervention effect; for ease of interpretation, only the
analysis of the untransformed data is reported. The primary
outcome, HbA1c and all continuous secondary outcomes
(total cholesterol, mean weight, BMI, mean waist circum-
ference) were analysed using mixed models for repeated
measurements with a random effect to account for variation
at baseline, and correlation between repeated measures
within individual participants was modelled by a first-order
autoregressive process. We considered the following poten-
tial covariates and factors: age; gender; ethnicity; education
level; employment status; smoking status; duration of
diabetes; presence of diabetic complications; previous use
of SMBG; cholesterol level; height; weight; BMI; and waist
circumference. Covariates with significant main effect and
key interaction were included in the models. Multiple
imputation (using iterative Markov chain Monte Carlo
methods) assessed the effect of missing data on the primary
comparison between the combined SMBG groups and the
control group. Twenty datasets with imputed values were
created post-randomization (convergence at 400 iterations,
psr<1.05). The primary comparison was undertaken in each
imputed dataset separately, with estimates pooled using
Rubin’s rules for comparison with analysis of the original
data.
All randomized participants were included in the primary,
secondary and safety analyses. The primary analysis of all
outcomes followed the intention-to-treat (ITT) principle. All
statistical analyses were performed with SPSS version 22 and
were verified by a second independent statistician.
Results
Between December 2012 and June 2015, 446 participants
met all eligibility criteria and were randomly assigned to a
control, an SMBG alone or an SMBG plus TeleCare
treatment group (Fig. 2). A total of 67 participants withdrew
from the study after randomization and 45 were lost to
follow-up. An additional 11 participants were withdrawn as
they were prescribed insulin therapy during the study
(Table S1). The numbers of participants prescribed insulin
were similar across the three groups (three, four and four
participants in groups 1, 2 and 3, respectively). There was no
significant difference in the proportions of people who left
the study between the control group (23.2%, 35/151) and the
combined SMBG group (29.8%, 88/295; chi-squared =2.21,
df=1, P=0.137). Neither was there a significant difference in
the percentage of people leaving the study between the
SMBG alone (32.7%, 48/147) and SMBG plus TeleCare
group (27.0%, 40/148; chi-squared =1.12, df=1, P=0.35).
Over half of those who left the study (58%, 65/112) did so
between the randomization and 3-month visit (Fig. S5). A
total of 323 participants (72%) completed the study.
Baseline characteristics for those randomized according to
treatment group are included in Table 1. At the start of the
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study a small number of participants (6%, 25/446) were
managing their diabetes through diet and exercise alone,
39% (174/446) were on monotherapy, and 55% (247/446)
were taking two or more oral antidiabetic medications.
Primary outcome measure
HbA1c levels decreased throughout the study in all three
groups; it decreased from 71 mmol/mol (8.7%) to 67 mmol/
mol (8.3%) in the control group and from 70 mmol/mol
(8.6%) to 57 mmol/mol (7.4%) in the combined SMBG
group. At 12 months, there was a greater reduction in mean
HbA1c in the combined SMBG group of 12.2 mmol/mol
(1.1%) compared to 3.3 mmol/mol (0.3%) in the control
group, with the difference being significant, after adjusting
for age at screening, gender, total cholesterol, BMI and
duration of diabetes (P<0.0001; Fig 3a). The estimated
treatment difference between the combined SMBG group
and the control group was 8.9 mmol/mol (95% CI –11.97 to
–5.84) or 0.8% (95% CI –1.10 to –0.54; P<0.0001). There
was no significant difference, however, in HbA1c reduction at
12 months between the two SMBG groups (P=0.458;
Table 2 and Fig 3b). The pooled estimate from the 20
imputed datasets showed similar findings. HbA1c analysis are
presented in Table 2 and Table S2.
Secondary outcomes
Of the 446 participants, 113 (25.3%) reached the target
HbA1c of ≤53 mmol/mol (≤7%) at 12 months, with signif-
icantly more participants in the combined SMBG group than
in the control group reaching the target (control group = 20/
151, 13.2%; combined SMBG = 93/295, 31.5%; chi-squared
=17.64, df=1, P <0.0001); however, the percentage of people
achieving the target was similar for the SMBG alone (46/147,
31.3%) and the SMBG plus TeleCare groups (47/148,
31.8%; chi-squared =0.007, df=1, P=0.93). Participants with
a lower baseline HbA1c concentration [hazard ratio (HR)
Assessed for eligibility
n=666
Excluded  n=220
¨ Not meeting inclusion criteria  n=205
¨ Withdrew consent  n=9
¨ Withdrew as prescribed insulin  n=1
- Lost to follow up  n=5
Group 1 – Control
Allocated and received no 
intervention
n=151
Group 3 – SMBG + TeleCare
Allocated and received SMBG with 
additional TeleCare intervention 
n=148
Allocation
Analysis
Follow-Up
Randomized 
n=446
Enrolment
Group 2 – SMBG Alone
Allocated and received SMBG 
intervention 
n=147
Analysed 
n=116
Analysed
n=108
Discontinued intervention n=35
Participant withdrawal n=16
Lost to follow up n=16
Withdrawn as prescribed insulin n=3
Discontinued intervention n=40
Participant withdrawal n=23
Lost to follow up n=13
Withdrawn as prescribed insulin n=4
Discontinued intervention n=48
Participant withdrawal n=28
Lost to follow up n=16
Withdrawn as prescribed insulin n=4
Analysed 
n=99
FIGURE 2 Consort diagram. SMBG, self-monitoring of blood glucose.
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1.58, 95% CI 1.28 to 1.97; P<0.0001], duration of diabetes
of < 5 years (HR 1.54, 95% CI 1.06 to 2.23; P=0.024) and
higher education status (HR 1.57, 95% CI 1.07 to 2.30;
P=0.02) were more likely to achieve the target HbA1c of ≤53
mmol/mol (≤7%) at 12 months.
After adjusting for baseline HbA1c concentration, duration
of diabetes and attainment of higher education, the probability
(HR) of participants achieving HbA1c ≤53 mmol/mol (≤7%)
within 12 months was 3.23 (95% CI 1.99 to 5.24; P<0.0001)
times higher in the combined SMBG group compared to the
control group (Fig. S6). There was no significant difference
between the SMBG alone and the SMBG plus TeleCare group
[HR 0.93, 95% CI 0.62 to 1.40; P=0.72 (Fig 4)].
Analyses of secondary outcomes are summarized in
Table 3. There was a statistically significant but not clinically
relevant reduction in total cholesterol levels at 3 months (–
0.28 mmol/l, 95% CI –0.50 to –0.05; P=0.017) and in waist
circumference at 12 months (–1.16 cm; 95% CI –2.25 to –
0.07; P=0.037) between the control group and the combined
SMBG group (Table S3).
For those who completed the study, the overall number of
diabetes medications prescribed increased over the study
period in 131 participants (40.6%), with 188 (58.2%)
remaining on the same total number of medications. A few
participants (4, 1.2%) in the SMBG alone group completed
the study taking fewer diabetes medications than at baseline
(Table 4). The SMBG participants were more likely to have
the number of medications increased during the study (chi-
squared =12.63, df=1, P<0.0001) in contrast to those in the
control group who were more likely to remain on the same
total number of diabetes medications (chi-squared =15.02,
df=1, P<0.001). The total number of diabetes medications
Table 1 Baseline characteristics of the three groups at randomization
Control (no SMBG) (n=151) SMBG alone (n=147) SMBG+ TeleCare (n=148)
Age, years 60.7 (10.98) 62.9 (9.34) 61.6 (9.82)
Men, n (%) 88 (58) 82 (56) 88 (60)
Ethnicity: white1, n (%) 135 (95) 137 (99) 133 (95)
Weight2, kg 95.3 (19.42) 95.0 (17.82) 95.8 (20.84)
BMI3, kg/m² 33.4 (6.03) 33.5 (6.72) 33.4 (6.66)
Waist circumference4, cm 110.4 (14.09) 109.5 (12.89) 109.9 (13.77)
HbA1c, mmol/mol 71.0 (11.74) 69.8 (11.83) 70.8 (12.53)
HbA1c, % 8.7 (1.07) 8.5 (1.08) 8.6 (1.15)
Total cholesterol5, mmol/l 4.7 (1.42) 4.8 (1.31) 4.5 (1.32)
Education6, n (%)
None 37 (25) 24 (16) 29 (20)
O’ level stage 37 (25) 51 (35) 41 (28)
Further education 23 (15) 27 (19) 25 (17)
Higher education 50 (33) 37 (25) 47 (32)
Other 4 (3) 7 (5) 6 (4)
Employment7, n (%)
Employed 57 (38) 36 (25) 43 (29)
Self-employed 17 (11) 7 (5) 9 (6)
Unemployed 9 (6) 14 (10) 12 (8)
Retired 68 (45) 90 (61) 83 (57)
Smoker8, n (%)
Yes 16 (11) 23 (16) 19 (13)
No 79 (52) 72 (49) 71 (48)
Previously 56 (37) 51 (35) 58 (39)
Duration of diabetes, n (%)
1 to 3 years 30 (20) 20 (14) 28 (19)
3 to 5 years 29 (19) 32 (22) 23 (16)
5 to 10 years 53 (35) 47 (32) 55 (37)
>10 years 39 (26) 48 (33) 42 (28)
Ever used SMBG, n % yes 103 (68) 104 (71) 103 (70)
Diabetic complications: yes9, n (%) 24 (16) 35 (25) 28 (19)
Diabetes medications10, n (%)
Monotherapy 63 (42) 54 (37) 57 (39)
Dual therapy 56 (37) 50 (34) 55 (37)
Triple therapy 25 (17) 29 (20) 28 (19)
4+ medications 2 (1) 0 2 (1)
No diabetes medications (diet only) 5 (3) 14 (9) 6 (4)
Diabetes knowledge
Percent with correct answers to ADKnowl Q 64.7 (25.2) 66.2 (25.2) 65.5 (25.3)
ADKnowl Q, Audit of Diabetes Knowledge questionnaire.
Data are mean (SD), unless otherwise indicated.
Missing data: ethnicity, n = 25; weight, n = 18; BMI, n = 13; waist circumference, n = 22; total cholesterol, n = 3; education, n = 1;
employment, n = 1; smoking, n = 1; complication, n = 11; and medication, n = 2.
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prescribed increased by 146, with the largest proportion being
dipeptidyl peptidase-4 inhibitors (17.0%) and sodium-glu-
cose co-transporter-2 inhibitors (13.3%; Table S4). The mean
(SD) number of medications increased in all three groups, from
1.7 at baseline to 2.0 (0.89) in the control group, 2.1 (0.96) in
the SMBG alone group and 2.4 (0.73) in the SMBG plus
TeleCare group by the end of the study period.
Engagement with the SMBG regimen
Adherence to the SMBG regimen, defined as having ≥ 80% of
expected total SMBG readings, was seen in 71% of the
participants who completed the study, and 80% of those
who completed also undertook paired testing, defined as two
or more readings in one day (Table 5). Those who completed
the study took part in an average of six TeleCare consulta-
tions over 12 months, with each TeleCare meeting lasting a
mean of 30 min. A large percentage of those assigned to
either of the SMBG groups (92.8%, 270/291) considered
SMBG a useful way of managing their diabetes at random-
ization. This increased to 96.5% (193/200) of those per-
forming SMBG at study completion (after 12 months). The
number of participants who said they would prefer not to
self-monitor reduced over time from 37 (12.7%) at random-
ization to 14 (7.0%) at 12 months. The number of
participants who found monitoring made them anxious
decreased over time from eight (3.4%) at 3 months to three
(1.5%) at 12 months, although there was an increase from
eight (3.4%) at 3 months to 10 (5.0%) at 12 months in those
who found the act of monitoring painful. By study comple-
tion, 88% of those using SMBG said they felt confident to
make lifestyle changes, with 83% saying they had made
lifestyle changes as a result of monitoring their BG profiles.
Within the SMBG groups 1032 episodes of BG levels <4.5
mmol/l were recorded by 130 participants (44%); the mean
number of episodes was 3, and the median (range) was 0 (0–
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58
63
68
73
78
7
7.5
8
8.5
9
Control Combined SMBG
m
m
ol
/m
ol
%
53
58
63
68
73
78
7
7.5
8
8.5
9
m
m
ol
/ 
m
ol
%
Control SMBG Alone SMBG+TeleCare
(a)
(b)
FIGURE 3 Comparison of mean (SEM) HbA1c between (a) the control and combined SMBG groups and (b) the three groups over the 12-month study
period.
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61) episodes (Table S5). Using the current clinical definition
of hypoglycaemia of <4.0 mmol/l [26], 328 episodes were
reported by 86 participants (29%); the mean number of
episodes was 1, and the median (range) was 0 (0–27)
episodes, while 13 episodes of clinically significant hypogly-
caemia (BG < 3.0 mmol/l) were recorded by 10 participants
(3%); the mean number of episodes was 0.04, and the
median (range) was 0 (0–2) episodes. There were no recorded
episodes of severe hypoglycaemia requiring third-party
assistance.
Adverse events
No related and unexpected serious adverse events were
reported within the study period. A total of 18 serious
adverse events were reported from 10 sites; these were
considered to be unrelated to the study. The HbA1c results
from the control group were monitored for deterioration by
the Data Monitoring Committee and as a result, 18 partic-
ipants in the control group were notified to their GP via their
local study team as their HbA1c had deteriorated by ≥15%
over a 6-month period. Two of these participants were
reported on two separate occasions. At no time was the
actual HbA1c result reported, only that there was deteriora-
tion. Fifteen of the 18 participants in the control group
whose GP was notified continued and completed the study.
The remaining three were lost to follow-up.
Discussion
The present RCT showed that structured SMBG reduced
HbA1c at 12 months by a statistically and clinically signif-
icant degree compared to a control group receiving usual
care not involving SMBG. Importantly, participants in the
Baseline 3 Month 6 Month 9 Month 12 Month
Visit
Control 151 131 127 115 116 
*SMBG alone     146    118 93 78 65
SMBG+TeleCare 148 126 105 87 74
Number at Risk
SMBG Alone – Control: HR 3.35 (95%CI 1.96 – 5.69) p<0.0001
SMBG with TeleCare – Control: HR 3.11 (95%CI 1.84 – 5.26) p<0.0001
SMBG with TeleCare – SMBG Alone: HR 0.93 (95%CI 0.62 – 1.40) p<0.72 
FIGURE 4 Achieving a target HbA1c ≤53 mmol/mol (7%). The graph shows time interval to event (achieving HbA1c ≤7% without relapse).
Significant covariates were HbA1c concentrations at baseline, duration with diabetes and attainment of higher education. *One missing value with
one of the significant covariates: education. HR, hazard ratio; SMBG, self-monitoring of blood glucose.
ª 2019 The Authors.
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structured SMBG group were three times more likely to
reach the HbA1c target of ≤53 mmol/mol (≤7%) than those
receiving standard care. Those participants with a lower
baseline HbA1c and shorter duration of diabetes were more
likely to achieve the target. Providing additional monthly
TeleCare support, as described, did not achieve any addi-
tional significant improvement in glycaemic control over and
above that seen in the structured SMBG-only group, but
there was a significant difference when compared to the
control group.
The findings from this RCT are in line with those studies in
people with Type 2 diabetes with sub-optimal control whilst
not on insulin therapy that have also employed structured
SMBG, having defined the timing and frequency of SMBG
and utilisation of results for adjustment of management [27].
The present study showed a reduction in HbA1c of just over
12 mmol/mol (1%) when structured SMBG is used, which is
comparable to the reduction in HbA1c after the addition of
an oral antidiabetic agent [28]. This is a larger change than
the majority of previous studies included in several meta-
analyses which showed only a moderate improvement in
HbA1c, with a difference of <0.5% between SMBG and usual
care [14]. A closer critique identified considerable hetero-
geneity among the former studies, particularly in terms of the
populations studied and interventions used [29]; however,
other studies that have used structured SMBG have also
shown benefit with regard to glycaemic control and quality
of life, and a reduction in depression and distress [7,8,30].
The increase in antidiabetic medication prescribed to the
SMBG cohort over the course of the present study illustrates
the potential of obtaining and using BG profiles to facilitate a
more targeted approach to prescribing and to overcome the
issue of clinical inertia in the treatment of hyperglycaemia in
Type 2 diabetes [31]. The relatively early improvement in
glycaemic control (HbA1c reduction of ~0.5% compared to
the control group) during the initial 3-month period suggests
that lifestyle changes (diet, physical fitness) must have been a
major contributor. Structured SMBG, in the form of paired
BG testing, allowed the participants to become quickly aware
of the impact of different dietary intake on their BG profiles.
They were therefore better able to adjust their food and drink
intake, along with adjusting physical activity, as part of a
‘self-learning’ process, thereby increasing their self-confi-
dence and providing the basis of a more meaningful
consultation with their healthcare professionals.
The SMBG schedule employed was designed to be a
reasonable balance between not being too onerous whilst
providing sufficient BG profiles to enable meaningful man-
agement decisions to be made. Despite this intention, 24% of
all study withdrawals in the SMBG groups were attributable
to difficulty adhering to the prescribed testing regimen. The
minimum testing frequency required to maintain engagement
whilst producing relevant information on which to base self-
management decisions needs to be determined on an
individual basis. The additional TeleCare support provided
to those undertaking structured SMBG did not achieve a
further improvement in HbA1c compared to those undertak-
ing structured SMBG alone; however, there was a significant
difference in HbA1c compared to the control group, which is
consistent with other studies in a recent meta-analysis
comparing the use of TeleCare to usual care in the manage-
ment of glycaemic control [23]. That review concluded that
Table 4 Number of people with medication changes during the study
Completers only
All participants
n=323
Control
n=116
SMBG
alone n=99
SMBG + TeleCare
n=108
Participants whose total number of
diabetes medications remained the same, n (%)
188 (58.2) 84 (72.4) 50 (50.5) 54 (50)
Participants whose total number of
diabetes medications increased, n (%)
131 (40.6) 32 (27.6) 45 (45.5) 54 (50)
Participants whose total number of diabetes
medications decreased, n (%)
4 (1.2) 0 4 (4) 0
Table 5 Engagement with the SMBG regimen
Completers only Combined SMBG n=207 SMBG alone n=99 SMBG +TeleCare n=108
No BG meter readings (missing data), n (%) 4 (1.9) 2 (2.0) 2 (1.9)
Adherence ≥80% total readings*, n (%) 148 (71.5) 68 (68.7) 80 (74.1)
Adherence paired testing† ≥80%, n (%) 166 (80.2) 76 (76.7) 90 (83.3)
BG, blood glucose.
*Total number of BG readings taken if testing regimen followed for 12-month period.
†Two or more BG readings per day.
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telemedicine had the greatest effect when introduced to those
with higher HbA1c levels and when used to facilitate
medication adjustment, as we observed using structured
SMBG. The TeleCare support provided in the present study
was monthly consultation via telephone contact, which
helped to maintain engagement with the study and with the
testing regime, although the glycaemic differences achieved
between the groups were not statistically significant.
In conclusion, structured SMBG, i.e. using paired BG
readings to generate BG profiles to identify patterns of
glycaemic abnormalities and taking appropriate action when
needed, should be available as part of the self-management
process for people with sub-optimally controlled Type 2
diabetes, including those not on insulin therapy. People living
with Type 2 diabetes should not be denied the option of
structured SMBG. They should receive the equipment and
training necessary to help them to record their BG results
accurately and in a meaningful way and should be provided
with the knowledge to interpret the results and take
appropriate action, such as making lifestyle changes or
seeking further advice. Those not able to engage fully with
the procedure will be identified through regular review
within the first few months and should either be offered
additional support or structured SMBG can be discontinued.
The present study supports the use of structured SMBG in
primary care. Unstructured SMBG, other than as advised in
the NICE guidance, should be regarded as a waste of
valuable time and resources and can no longer be justified.
Healthcare policies in relation to people with sub-optimally
controlled type 2 diabetes not on insulin therapy should
reflect these observations.
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